Integrated control and sensing platform for biopharmaceutical cultivation process high-throughput development and production


Start Date
End Date
IMI2 - Call 10
Grant agreement number

Type of Action: 
RIA (Research and Innovation Action)

IMI Funding
4 700 000
EFPIA in kind
4 700 000
Total Cost
9 400 000


Animal cell technology is now widely used in the development and manufacture of biopharmaceuticals, vaccines and advanced therapies. The quality of the cell culture determines the quality of the final product. The aim of iCONSENSUS is to achieve a faster, safer and more cost-effective process for the development and manufacture of these products. Among other things, the project will develop innovative analytical, hardware, software and high-throughput tools for the development, monitoring and control of mammalian cell cultivation processes for producing biopharmaceuticals.

Participants Show participants on map

EFPIA companies
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • Byondis BV, Nijmegen, Netherlands
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • Rentschler Biopharma Se, Laupheim, Germany
  • Sanofi-Aventis Deutschland GMBH, Frankfurt / Main, Germany
  • UCB Biopharma, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Kungliga Tekniska Hoegskolan, Stockholm, Sweden
  • Rheinisch-Westfaelische Technische Hochschule Aachen, Aachen, Germany
  • Universitaet Hohenheim, Stuttgart, Germany
  • Universite De Mons, Mons, Belgium
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Iprasense, Clapiers, France
  • Ipratech SA, Mons, Belgium
  • Kantisto BV, Baarn, Netherlands
  • Micronit BV, Enschede, Netherlands
  • Paia Biotech GMBH, Köln, Germany
  • Presens Precision Sensing GMBH, Regensburg, Germany
Associated partners
  • Ramcon A/S, Birkerod, Denmark
Non EFPIA companies
  • Beckman Coulter GMBH, Krefeld, Germany
Project leader
Luc Kupers